mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms

NCT04393246 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

454

Enrollment

OTHER

Sponsor class

Conditions

COVID-19

Interventions

DRUG: EDP1815
DRUG: Dapagliflozin
DRUG: Ambrisentan
OTHER: Standard of care

Sponsor

Cambridge University Hospitals NHS Foundation Trust